Type 2 diabetes (T2DM) is a rapidly growing public health problem. It is associated with an increased risk of fracture, particularly of the hip, despite normal or high bone mineral density. Longer duration of disease and poor glycaemic control are both associated with higher fracture risk. The factors underlying increased fracture risk have not been clearly established, but increased falls risk, obesity, sarcopenia and co-morbidities are likely to contribute. The basis for reduced bone strength despite higher bone mineral density remains to be fully elucidated. Bone turnover is reduced in individuals with T2DM, with evidence of impaired bone formation. Most studies indicate normal or superior trabecular bone structure although reduced lumbar spine trabecular bone score (TBS) has been reported. Deficits in cortical bone structure have been demonstrated in some, but not all, studies whilst reduced bone material strength index (BMSi), as assessed by microindentation, has been a consistent finding. Accumulation of advanced glycation end products in bone may also contribute to reduced bone strength. The use of FRAX in individuals with T2DM underestimates fracture probability. Clinical management should focus on falls prevention strategies, avoidance of known risk factors, maintenance of good glycaemic control and bone protective intervention in individuals at high risk of fracture. Dietary and surgical strategies to reduce weight have beneficial effects on diabetes but may have adverse effects on skeletal health.
Introduction
It is estimated that 422 million people worldwide have diabetes [1] . Type 2 diabetes (T2DM) accounts for >90% of cases and is characterized by insulin resistance, often accompanied by relative insulin deficiency [2] . In the last few decades, there has been a dramatic increase in the prevalence of diabetes, particularly in middle and lower income countries, and the number of affected people has almost quadrupled since 1980. This has been accompanied by a steep rise in the prevalence of obesity, a major risk factor for the development of T2DM [3] .
Increased fracture risk is a recognized complication of T2DM but much remains to be learned about its causes and management. This review covers the epidemiology, pathogenesis and pathophysiology of increased bone fragility and fractures and considers possible preventive strategies.
Epidemiology
Although estimates of fracture risk associated with T2DM show substantial variation, most studies indicate a modest increase at some sites, albeit less than that associated with T1DM. A number of factors are likely to contribute to this variability, including misclassification of T1DM and T2DM and differences in study design and characteristics of the population studied. Increased risk of hip fracture has been most consistently reported, [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] although this finding has not been universal [23] [24] [25] and in some studies has varied according to age and gender. Increased fracture risk at the wrist [8, 22] , proximal humerus [13, 16, 24] , lower leg [16, 22] , foot [15, 16] , ribs [15] and spine [15, 16, 26] has also been described, although again with some inconsistency between studies.
The results of three meta-analyses of fracture risk associated with T2DM are summarized in Table 1 [5, 6, [27] [28] [29] [30] . All show an increase in hip fracture risk; in addition, increased risk of spine fracture was reported in two studies, and increased risk of foot fracture and wrist fracture was described in the meta-analysis of Moayeri et al. and Vestergaard et al., respectively. Increased risk of all fractures was reported by Moayeri et al. [27] ; in the meta-analysis of Vestergaard et al. [6] , the risk of all fractures was not significantly increased and there was marked heterogeneity between the studies included, three showing increased risk and two showing decreased risk.
Taken together these studies provide strong evidence that T2DM is associated with an increased risk of hip fracture, and weaker evidence that the risk of wrist, spine and foot fracture is also increased. Longer duration of disease is associated with higher fracture risk [14, 24, 31] , and there is also some evidence for an association with poor glycaemic control [25] .
Pathogenesis of fractures associated with T2DM
A number of factors may contribute to the increased fracture risk associated with T2DM. These include obesity, increased risk of falls, sarcopenia, co-morbidities associated with diabetes and anti-diabetic drugs. In addition, there may be direct effects of diabetes on bone that impact on bone quality and strength.
Obesity
The strong association between T2DM and obesity raises the question of the extent to which obesity per se contributes to bone fragility in T2DM. Bone mineral density (BMD) is positively associated with body mass index [32] , and this can be regarded as a physiological phenomenon in which skeletal mass adjusts to the prevailing mechanical loads. Thus, the higher BMD in obese individuals, including those with T2DM, does not necessarily confer greater protection against fracture and there may be a threshold of body mass above which the skeleton is no longer able to adapt.
Despite normal or high BMD, obesity is associated with increased risk of fracture at some sites, particularly the ankle and proximal humerus, whereas the risk of hip and wrist fracture is decreased relative to people of normal weight [33] [34] [35] [36] [37] [38] [39] [40] [41] . Whilst reports in people with T2DM of increased risk of humerus, foot and ankle fracture would be consistent with an effect of obesity per se, the increased risk of hip and wrist fracture in T2DM shows a pattern opposite to that observed in obese individuals, indicating some divergence of causal pathways between obesity and diabetes. Nevertheless, obesity likely plays a role in the pathogenesis of fracture associated with T2DM, through factors such as increased risk and impact of falls, immobility, inflammation, vitamin D insufficiency, hypogonadism (in men) and adverse effects of adipose tissue on bone remodelling [42] [43] [44] [45] [46] [47] .
Increased risk of falls
Increased risk of falling in individuals with diabetes has been demonstrated in a number of studies [48] . In addition to the effect of obesity in increasing the risk of falls [33, 49] diabetic comorbidities also contribute, these include visual impairment due to cataracts or retinopathy, cardiac arrhythmias due to cardiovascular disease, and peripheral neuropathy. Hypoglycaemia is also a risk factor for falls [50] .
Sarcopenia
The prevalence of sarcopenia is increased in diabetics, particularly in older individuals, and there is evidence that some of the effects on muscle are directly mediated by diabetes [51] [52] [53] . Associations between loss of muscle mass and function and both duration of diabetes and poor glycaemic control have been reported [54] [55] [56] and in a large cross-sectional study of people aged 65 years or over, T2DM was shown to be associated with reduced muscle strength, impaired gait and slow walking speeds, independent of the presence of peripheral neuropathy or peripheral vascular disease [57] . Muscle density was significantly lower in diabetic individuals; this difference was largely attenuated after adjustment for BMI, indicating that infiltration of muscle by fat plays an important role in the observed muscle dysfunction.
Co-morbidities associated with diabetes
In nondiabetic populations, an increasing number of medical conditions are recognized as being associated with increased fracture risk [58] . Some of these, for example heart disease, stroke, renal dysfunction and cognitive impairment, are common complications of diabetes and are likely to contribute to increased risk of fracture through a variety of mechanisms including falls, reduced mobility and systemic inflammation.
Altered glucose metabolism
T2DM is characterized by insulin resistance and hyperinsulinaemia, both of which have effects on bone. High levels of circulating insulin may contribute to high BMD [59] , and there is evidence in preclinical models that altered insulin levels and insulin resistance affect bone remodelling via direct effects on osteoblasts, osteoclasts and osteocytes, all of which express insulin receptors [60] . Hyperglycaemia is associated with accumulation of advanced glycation end products (AGEs) in bone matrix [61] , and there is evidence from preclinical studies that it inhibits bone formation, an effect mediated at least in part by increased osteocyte sclerostin production [62] .
Vitamin D insufficiency
T2DM is associated with an increased prevalence of vitamin D insufficiency [63] , which may partly reflect the strong association of the disease with obesity. Interestingly, however, whereas in obesity some studies have reported increased serum levels of parathyroid hormone (PTH) [64, 65] , T2DM has been associated with reduced PTH levels and attenuation of the normal PTH response to vitamin D deficiency [66, 67] .
There is evidence that vitamin D plays a role both in the development of T2DM and in glycaemic control. Vitamin D receptors are expressed in the beta cells of the pancreas and may have direct effects on insulin production; in addition, antiinflammatory effects of vitamin D may modulate insulin resistance [68] . These observations provide an additional rationale for vitamin D supplementation in T2DM; however, consistent benefits of supplementation on glycaemic control have not been demonstrated in meta-analyses [68, 69] .
Anti-diabetic medications (Table 2) Drugs used in the treatment of diabetes may have both direct and indirect effects on bone health and fracture risk. Reduction in diabetic co-morbidities due to improved glycaemic control is likely to be beneficial, but treatment-induced hypoglycaemia may increase the risk of falls. In addition, some drugs used for treatment of diabetes have direct effects on bone. Insulin therapy is used only in a small minority of people with T2DM and will not be considered further.
Sulphonylureas
Direct effects of sulphonylureas on bone have not been well investigated [70] . Although most studies to date indicate a protective or neutral effect of sulphonylureas on fracture risk [8, 15] , hypoglycaemia is a common side effect of these drugs and the risk of fall-related fractures might therefore be increased [71] . In support of this contention, a recent study demonstrated that current, but not ever, use of sulphonylureas was associated with increased risk of hip fracture [72] .
Metformin
Preclinical studies indicate that metformin stimulates bone formation and inhibits bone resorption [73] . However, data on fracture risk in humans are conflicting, both decreased fracture risk and no effect being reported [8, 15] .
Thiazolidinediones
Thiazolidinediones activate PPARc (peroxisome proliferator-activated receptor gamma), resulting in stimulation of adipogenesis and suppression of osteoblastogenesis [74] . In a meta-analysis of longterm use of thiazolidinediones and fractures in T2DM, Loke et al. [75] found a doubling of fracture risk in women, most fractures occurring in the proximal humerus, hands and feet; no significant increase was seen in men. In contrast, in a large prospective cohort study from Canada, increased fracture risk was seen in both men and women [76] .
Incretin-based treatments
Incretins are gastrointestinal hormones that inhibit the release of glucagon and stimulate insulin production. Incretin-based drugs used in the treatment of T2DM include glucagon-like peptide-1 receptor agonists (GLP-1-RAs) and inhibitors of the dipeptidyl peptidase-4 enzyme (DPP-4). Their effect on fracture risk in subjects with T2DM has not been clearly established; in one metaanalysis, no effect on fracture risk was demonstrated when compared either to placebo or to other anti-diabetic drugs [77] , whereas in another meta-analysis, increased fracture risk was seen in individuals treated with exenatide, but nonvertebral fractures were reduced in those treated with liraglutide in comparison with other medications [78] . For DPP-4 inhibitors, the data are also conflicting. In a meta-analysis, Monami et al. reported a reduced risk of fractures that persisted after the exclusion of comparisons with thiazolidinediones or sulfonylureas [79] , and decreased risk of fracture was also reported in a study from Germany in individuals treated with DPP-4 inhibitors in combination with metformin when compared to metformin alone [80] . In contrast, no difference in fracture risk was found in a large retrospective study or in two meta-analyses [81] [82] [83] . Taken together, these results are mostly consistent with a neutral or beneficial effect of incretin-based treatments on fracture risk [84] . However, the small number of fracture events in most of the studies reduces the certainty of the conclusions that can be drawn.
Sodium glucose co-transporter 2 (SGLT2) inhibitors SGLT2 inhibitors act by reducing renal proximal tubular reabsorption of glucose. They also increase phosphate tubular reabsorption and may therefore induce secondary hyperparathyroidism, with adverse effects on bone. In a pooled analysis of 12 randomized controlled trials, Ptasynka reported no effects on fracture risk in individuals treated with dapagliflozin [85] , but in another study of subjects with T2DM and moderate renal impairment, an increased fracture incidence was seen with dapagliflozin treatment when compared to placebo [86] . One meta-analysis showed no increased in fracture risk in individuals treated with SGLT2 inhibitors (pooled analysis for canagliflozin, dapagliflozin, or empagliflozin), although the follow-up period was short and the number of fractures was low [87] , and in another metaanalysis, no significant increase in the risk of fracture was reported in individuals treated with any of the three drugs [88] . However, canagliflozin was associated with increased fracture risk in one study when compared either to placebo or other anti-diabetic medications [89] . At present, therefore, there is uncertainty about the effects of these drugs on fracture risk and whether there are true differences between drugs. For canagliflozin, but not for other SGLT2 inhibitors, the FDA recently changed prescribing information to contain a warning that factors contributing to fracture risk should be considered before the drug is prescribed. Pathophysiology (Table 3) Whilst the normal or high BMD in many individuals with T2DM may be largely attributable to obesity, the increased risk of hip fracture and, in some studies, spine and wrist fracture in T2DM indicates that the pathophysiological changes leading to fracture in the two conditions are not identical. In T2DM, the higher BMD remains after adjustment for BMI [21] and although the inverse relationship between BMD and fracture risk that exists in nondiabetics is also seen in T2DM, the higher fracture risk cannot be explained on the basis of BMD alone.
Bone remodelling
There is a paucity of histomorphometric studies in individuals with T2DM. Reduced cancellous bone volume and cortical thickness were reported in iliac crest bone obtained from 26 individuals with T2DM; significantly lower osteoid volume, osteoid thickness and osteoblast surface were also documented in comparison to age-matched controls [90] . Subsequent studies in which dynamic indices of bone remodelling were assessed have shown decreased bone formation, with reduction in the mineralizing surface, bone formation rate, mineral apposition rate and osteoblast surface [91, 92] . In the one study in which quantitative data on bone resorption were provided, eroded surface and osteoclast surface were similar in biopsies from people with T2DM and controls [92] . Consistent with this evidence of low bone turnover, a metaanalysis of biochemical turnover markers in individuals with diabetes (T1DM or T2DM) showed significantly reduced levels of serum osteocalcin and C-terminal cross-linked telopeptide (CTX), although other markers, including bone-specific alkaline phosphatase, did not differ from normal [93] . A subsequent systematic review from the same group reported essentially similar findings [94] . It should be noted, however, that serum CTX levels may be underestimated in individuals with diabetes as a result of reduced enzymatic crosslinking of bone collagen by lysyl oxidase leading to decreased release of cross-linked telopeptides. Increased serum sclerostin levels have also been described in T2DM [95] [96] [97] , indicating a possible pathogenetic role in the reduced bone formation characteristic of this condition.
Bone microarchitecture
Application of high resolution peripheral quantitative computed tomography (HRpQCT) to the study of bone structure in subjects with T2DM has produced conflicting results. In a small crosssectional study of 19 elderly women with T2DM, cortical porosity was higher in the radius and tibia when compared to control values, and in the radius, compressive bone strength, estimated using finite element analysis (FEA), was significantly lower [98] . In a cohort of 190 older men with T2DM participating in the MrOS study, total bone cross-sectional area in the radius and tibia was lower in diabetics than nondiabetics and bending strength was reduced in cortical regions relative to body weight. In trabecular regions, bone strength was similar to that of controls, the higher trabecular volumetric BMD compensating for a lower total bone area in T2DM [99] . Patsch et al. compared the structural characteristics of bone in the radius and tibia in diabetic and nondiabetic postmenopausal women with or without fragility fracture [100] . Significantly higher cortical porosity and lower bone strength (stiffness, failure load and cortical load fraction) were demonstrated in diabetic women with fracture when compared to those without fracture, whereas these indices did not differ between nondiabetic women with or without fracture. Further investigation of this cohort revealed that the increased porosity was seen in the midcortical and periosteal, but not endosteal, regions of the cortex [101] . Interestingly, in this study cortical porosity in diabetic women without fracture did not differ significantly from that of healthy controls. In a study in African American women with T2DM Yu et al. [102] reported higher cortical porosity and lower cortical vBMD and tissue mineral density at the radius compared to nondiabetic controls. In another cross-sectional study of 51 individuals with T2DM, cortical bone deficits were only seen in a subgroup with microvascular complications [103] .
Modest deficits in cortical bone structure in individuals with T2DM have also been reported in a larger, community-based study of men and women age 40-87 years (mean 64), of whom 129 were diabetic [104] . After adjustment for age, sex, weight and height, subjects with T2DM had significantly lower cortical vBMD, higher cortical porosity and smaller cross-sectional area at the tibia, although not the radius. Analysis of those individuals with a prior fracture revealed lower cortical vBMD and higher cortical porosity in the tibia in diabetics compared to nondiabetics. There was a trend towards lower FEA-estimated failure load at the tibia, although this did not achieve statistical significance. Indices of trabecular bone structure were similar or more favourable in individuals with T2DM.
Other studies, however, have not demonstrated abnormalities of bone structure associated with T2DM. In a cross-sectional comparison of 25 postmenopausal women with T2DM and 25 nondiabetic controls, no significant differences in bone structure assessed by HRpQCT were demonstrated; surprisingly, in this cohort areal BMD did not differ between diabetics and controls [105] . Similarly, Farr et al. [106] reported no significant differences in peripheral cortical and trabecular bone microarchitecture in 30 postmenopausal women with T2DM when compared to non-diabetic controls after adjustment for BMI (although there was a nonsignificant tendency for higher radial cortical porosity in the diabetic women). Nilsson et al. [107] recruited a population-based sample of 99 women aged 75-80 years with T2DM and 954 controls. Measures of trabecular and cortical bone microarchitecture and bone strength estimated by FEA generally exhibited a more favourable profile in the diabetic women compared to the controls. Although significantly greater cortical porosity was shown at the distal radius site, this finding was not replicated at the more proximal site or in the tibia.
The majority of studies using HRpQCT in T2DM have demonstrated either normal or superior trabecular bone structure when compared to nondiabetic subjects. In contrast, however, reduced lumbar spine trabecular bone score (TBS) in T2DM has been reported in a number of studies [108] [109] [110] . TBS is an indirect and as yet not welldefined index of trabecular bone structure and has predictive value for fracture independent of BMD in both diabetics and nondiabetics [111] . It should be noted that measurements of TBS may be unreliable in very obese subjects; nevertheless, the consistent finding of a reduced TBS in T2DM is interesting and suggests that at least at some skeletal sites, trabecular bone abnormalities may contribute to bone fragility in T2DM.
The effects of T2DM on volumetric BMD, bone geometry and strength in the proximal femur have been investigated in two studies. Using singleenergy QCT, higher trabecular vBMD was shown in the hip in 49 subjects with T2DM when compared to nondiabetic subjects, whereas cortical vBMD, bone cross-sectional area and cortical thickness were similar in diabetics and controls. Although measures of bone strength were generally greater in diabetic subjects, the load-to-strength ratios were similar to those of controls, because of greater body weight in the diabetics [112] . Heilmeier et al.
[113] compared proximal femoral vBMD and geometry in a cross-sectional study of postmenopausal women with T2DM with and without fracture. Significantly lower integral and trabecular, but not cortical vBMD, and lower cortical thickness were demonstrated in the subjects with fracture.
Microindentation
Microindentation using the OsteoProbe technique is a relatively new technique that measures the depth of indentation and hence the resistance to penetration at the periosteal surface of the tibia. It is believed to assess cracking of bone matrix, based on the assumption that the degree of separation of mineralized collagen fibrils is a determinant of crack initiation and bone toughness [114] . Reductions in the bone material strength index (BMSi) provided by the measurement have been shown in several conditions, including postmenopausal osteoporosis and atypical fractures, these differences persisting after adjustment for BMD [115] [116] [117] . The technique therefore shows potential for the determination of bone material abnormalities that contribute to bone fragility and are at least partially independent of BMD measurements. Further studies are needed, however, to establish the relationship between BMSi and traditional measures of bone strength and the predictive value of BMSi for fragility fracture.
In contrast to the conflicting results using HRpQCT-derived FEA to estimate bone strength, a consistent reduction in bone material strength assessed using microindentation has been shown in the three studies reported to date. In a study of 60 postmenopausal women, 30 of who had T2DM (duration >10 years), BMSi was shown to be significantly reduced in the diabetic women both before and after adjustment for BMI; glycated haemoglobin levels were inversely related to BMSi [106] . Furst et al. [118] reported significantly reduced BMSi values in 16 postmenopausal women with T2DM when compared to controls, with a significant inverse correlation between BMSi and duration of disease. Skin autofluorescence, used as a surrogate for AGEs, was also inversely associated with BMSi. Finally, in the larger study of Nilsson et al. [107] , BMSi was significantly reduced in women with T2DM, before and after adjustment for multiple covariates including BMI.
The data reviewed above are thus somewhat conflicting, but point to a possible role for cortical bone deficits in the pathogenesis of bone fragility in T2DM. Possible reasons for the variable findings include differences in the study design and characteristics of the population studied (e.g. age, gender, duration of disease). In addition, inaccuracies in defining the endosteal margin of bone, particularly in older people and at more distal sites, and the use of a fixed offset distance rather than one scaled to individual bone length for distal measurements are likely to contribute to the different findings reported. The mechanisms responsible for alterations in cortical bone structure have not been identified. A recent study in a cohort of population-based women demonstrating that subcutaneous fat mass in the tibia is inversely related to BMSi and cortical vBMD, and positively associated with cortical porosity suggests that increased adiposity may contribute but further studies are needed [119] . Finally, the sitespecificity of alterations in cortical bone structure merits further investigation. In particular, given the increased risk of hip fracture in individuals with T2DM, more information is required about changes in bone structure and strength in the proximal femur.
Alterations in bone matrix: advanced glycation end products (AGEs)
AGEs are a diverse group of compounds produced by nonenzymatic glycation of various proteins, including type 1 collagen. In preclinical studies, they have been shown to have inhibitory effects on osteoblasts and osteoclasts [120] and their accumulation in bone matrix has adverse effects on biomechanical properties [121, 122] . Data on circulating and bone levels of AGEs in humans with diabetes are relatively sparse, although increased serum levels of AGEs have been reported in subjects with diabetes [123] . Positive correlations between serum and urine levels of pentosidine and fracture risk in T2DM that persist after adjustment for BMD have been demonstrated [124, 125] . There is therefore some circumstantial evidence for a pathogenetic role for AGEs in the bone fragility associated with T2DM, but further studies are required to provide confirmation. In particular, more information is needed about the extent of accumulation and biomechanical consequences of AGEs in human diabetic bone.
Clinical management
Fracture risk assessment In view of the normal or high BMD associated with T2DM, prediction of fracture risk in affected individuals is an important topic. In 16 885 older community-dwelling adults from the USA who had taken part in three large prospective observational studies, lower femoral neck BMD and higher FRAX score were associated with higher risk of fracture in individuals with T2DM. FRAX showed a similar ability to discriminate between diabetics and nondiabetics who developed fracture, but underestimated the risk of both hip and nonspine fractures in the diabetic population [126] . Similar results were reported by Giangregorio et al. [127] in a large clinical database from Manitoba of individuals' age 50 years and older. In a subsequent study from Manitoba, the independent association between diabetes (T1DM and T2DM combined) and major osteoporotic fractures and hip fractures was confirmed; additionally, it was shown that diabetes did not modify the effect of FRAX risk factors except in the case of age, which had a stronger effect on risk of hip fracture in younger individuals [128] . Further analysis, limited to postmenopausal women, demonstrated that the duration of diabetes is an important determinant of fracture risk, and that underestimation of fracture probability by FRAX is substantially greater in women with disease duration of 10 years or longer [31] .
These data demonstrate that FRAX underestimates fracture risk in people with T2DM, particularly in those with longer disease duration. Possible reasons for this include increased risk of falls, altered bone quality and strength, and alterations in bone microarchitecture that are not captured by measurements of areal BMD. Adjustment of FRAXderived probability for TBS may improve fracture prediction; it has also been suggested that substitution of T2DM for rheumatoid arthritis in the FRAX questionnaire and reducing the BMD T-score by 0.5 SD may be appropriate [129] . However, until further refinements of fracture risk estimation in T2DM have been validated, the most important message for those in clinical practice is that BMD with or without FRAX underestimates fracture risk in T2DM, particularly in those with long disease duration.
Management strategies

General measures
Currently, there is only very limited evidence on which to base strategies for prevention and treatment of bone disease associated with T2DM. Maintenance of good glycaemic control and avoidance of hypoglycaemia may help to reduce fracture risk. Avoidance of anti-diabetic medications with adverse skeletal effects should be considered in individuals with additional risk factors for fracture.
Other lifestyle measures such as ensuring adequate dietary calcium intake and vitamin D status, cessation of smoking, avoidance of alcohol abuse and regular physical activity should be advised.
Falls risk should be assessed and where appropriate, preventive measures implemented. A systematic review demonstrated that falls prevention programmes in subjects with T2DM and peripheral neuropathy improved balance and walking without risk of serious adverse events, although there are insufficient data to assess any impact on the frequency of falls [130] . Similar results were reported in a meta-analysis of the effectiveness of falls prevention programmes in older adults with diabetes [131] . These studies highlight the need for further research in this area, in particular the effects of intervention programmes on fracture risk.
Weight reduction
Weight reduction is clearly a desirable target for many health outcomes in individuals with T2DM. However, as weight loss is associated with bone loss, adverse skeletal effects might be expected [132] [133] [134] . There is evidence that when dietinduced weight loss is accompanied by exercise regimens, bone loss can be attenuated or prevented in obese elderly individuals and physical function improves [135] .
Bariatric surgery is increasingly used as a treatment for T2DM in obese individuals. Some studies have shown an increase in fracture risk following bariatric surgery, although this finding has not been universal [136] [137] [138] [139] [140] . Similar rates of bone loss were demonstrated after surgery in diabetic individuals when compared to nondiabetic populations [138] but in another study in which people with T2DM undergoing surgery were compared with those receiving intensive medical therapy, numerically more falls and fractures were seen in the former group [141] . The skeletal effects of bariatric surgery may vary according to the procedure involved, and further investigation of the longterm effects of different surgical approaches in diabetic populations is required.
Bone protective medication
Evidence for reduced bone turnover and impaired bone formation in T2DM provides some rationale for the use of anabolic agents in those at high risk of fracture, but there have been no studies in which the effects of anti-resorptive and anabolic agents have been compared in individuals with T2DM nor are data on fracture risk reduction available. Subgroup analyses of pivotal randomized controlled trials indicate that similar increases in BMD are seen in diabetic and nondiabetic individuals treated with alendronate or raloxifene [142, 143] , and in a large cohort study from Denmark, similar reductions in fracture rate were observed in response to bisphosphonate or raloxifene therapy in people with T1DM, T2DM and nondiabetics [144] . Finally, subgroup analysis of the Direct Assessment of Nonvertebral fractures in Community Experience (DANCE) observational study in 291 individuals with T2DM and 3751 nondiabetics showed similar benefits of teriparatide in the two groups, as assessed by BMD, nonvertebral fracture incidence and back pain [145] .
Conclusions
T2DM is associated with increased risk of fracture, particularly at the hip. The pathogenesis of fracture is multifactorial; obesity, increased risk of falls, sarcopenia, co-morbidities, altered glucose metabolism and the effects of anti-diabetic medications all contribute (Fig. 1) . The causes of increased bone fragility associated with T2DM, which occurs despite normal or high BMD, require further investigation but adverse effects of AGEs on bone matrix and altered bone microarchitecture may play a role.
Optimal management strategies to reduce fracture risk in individuals with T2DM remain to be established. FRAX, with or without BMD, underestimates fracture risk. Assessment of falls risk should be undertaken with implementation of preventive measures where appropriate. Good glycaemic control should be maintained and lifestyle measures to improve bone health recommended. Current evidence indicates that anti-resorptive drugs and teriparatide produce similar BMD responses to those seen in nondiabetics, but further studies are required to establish the effects of pharmacological interventions on fracture outcomes and to develop appropriate intervention thresholds.
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